Emergingby GlyphXOMA Royalty agrees to acquire Generation Bio
The deal brings Generation Bio's cell-targeted LNP platform into XOMA's portfolio.
Nanotechnologysec.gov
Generation Bio
Public companyUS1 field
Where it works
| Technology | ||
|---|---|---|
| NanotechnologyDeveloped cell-targeted lipid nanoparticles for siRNA; agreed to be acquired by XOMA Royalty. | Developed cell-targeted lipid nanoparticles for siRNA; agreed to be acquired by XOMA Royalty. | sec.gov |
Events
About
- Source
- sec.gov (filing, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Oct 6, 2026
- Across Glyph
- Generation Bio on Companies
Generation Bio
Joined in Nanotechnology. Developed cell-targeted lipid nanoparticles for siRNA; agreed to be acquired by XOMA Royalty.
Generation Bio
Added in Nanotechnology. Developed cell-targeted lipid nanoparticles for siRNA; agreed to be acquired by XOMA Royalty.